![Brad VanWagenen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brad VanWagenen
Corporate Officer/Principal at Prolexys Pharmaceuticals, Inc.
Brad VanWagenen active positions
Companies | Position | Start | End |
---|---|---|---|
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | 31/10/2007 | - |
Career history of Brad VanWagenen
Former positions of Brad VanWagenen
Companies | Position | Start | End |
---|---|---|---|
NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Training of Brad VanWagenen
Southern Utah University | Undergraduate Degree |
Montana State University | Graduate Degree |
Pacific University | Graduate Degree |
Statistics
International
United States | 6 |
Operational
Corporate Officer/Principal | 2 |
Graduate Degree | 2 |
Undergraduate Degree | 1 |
Sectoral
Consumer Services | 4 |
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Prolexys Pharmaceuticals, Inc.
![]() Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
NPS Pharmaceuticals, Inc.
![]() NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
- Stock Market
- Insiders
- Brad VanWagenen
- Experience